PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34321273-12	2021	Either MVA-OVA alone or combined with simvastatin augmented B cells, CD4+ lymphocytes, CD8+ lymphocytes, and tumor-specific CD8+ in the tumor-draining lymph nodes.	Simvastatin	38-49	CD4 molecule	Homo sapiens	69-72	
18453621-0	2008	Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.	Simvastatin	0-11	CD4 molecule	Homo sapiens	157-160	
18453621-4	2008	Simvastatin also induced IFN-gamma, IL-4, and IL-27 production in monocytes, which together inhibited IL-17 transcription and secretion in CD4(+) T cells.	Simvastatin	0-11	CD4 molecule	Homo sapiens	139-142	
18453621-6	2008	Furthermore, simvastatin directly inhibited the expression of retinoic acid-related orphan nuclear hormone receptor C, a transcription factor that controls IL-17 production in CD4(+) T cells.	Simvastatin	13-24	CD4 molecule	Homo sapiens	176-179	
18484192-2	2008	Our recent study demonstrated that simvastatin exerts an independent immunomodulatory effect on the human monocytes and CD4+ cells.	Simvastatin	35-46	CD4 molecule	Homo sapiens	120-123	
18484192-3	2008	In addition to the statin-mediated effect on the monocyte cytokine production, which regulates Th17 cell differentiation, simvastatin directly inhibits IL-17 production in CD4+ cells, which may collectively inhibit the autoimmune response in multiple sclerosis (MS), a central nervous system (CNS) inflammatory demyelinating disease.	Simvastatin	122-133	CD4 molecule	Homo sapiens	172-175	
17520029-2	2007	PRINCIPLE FINDINGS: Here we demonstrate that treatment of an enriched CD4(+) lymphocyte population with lovastatin (Lov), mevastatin (Mev) and simvastatin (activated and non-activated, Sim(A) and Sim(N), respectively) can reduce the cell surface expression of the CC-chemokine receptor CCR5 (P<0.01 for Sim(A) and Lov).	Simvastatin	143-154	CD4 molecule	Homo sapiens	70-73	
17929126-10	2007	Immunological assessment in peripheral blood revealed that the Th1/Th2 and CD4/CD8 ratios were significantly reduced by simvastatin.	Simvastatin	120-131	CD4 molecule	Homo sapiens	75-78	
17929126-12	2007	Immunomodulation through the alteration of Th1/Th2 and CD4/CD8 ratios may be a pharmacological mechanism in the anti-rheumatic effect of low-dosage simvastatin.	Simvastatin	148-159	CD4 molecule	Homo sapiens	55-58	
34687147-4	2022	In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC.	Simvastatin	46-57	CD4 molecule	Homo sapiens	162-165	
24159421-4	2013	At concentrations that inhibited anti-CD3/28-stimulated T-cell proliferation (P < 0.01), simvastatin significantly decreased intracellular CD4(+) T-cell expression of IFN-gamma (P < 0.01) to levels similar to those induced by conventional immunosuppressives.	Simvastatin	92-103	CD4 molecule	Homo sapiens	142-145	
17929126-0	2007	Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios.	Simvastatin	22-33	CD4 molecule	Homo sapiens	91-94	
31269241-5	2019	We found that treatment of TSLP-stimulated DCs with either pitavastatin or simvastatin suppressed both the DC-mediated inflammatory Th2 cell differentiation and CRTH2+ CD4+ memory Th2 cell expansion and also repressed the expressions of OX40L and CCL17 by DCs.	Simvastatin	75-86	CD4 molecule	Homo sapiens	168-171